Bluejay Diagnostics Soars 82.89% on SYMON-II Study Launch

On June 6, 2025, Bluejay Diagnostics skyrocketed by 82.89% in pre-market trading, marking a significant surge in its stock price.

Bluejay Diagnostics has recently launched the SYMON-II clinical study, a move that underscores the company's dedication to advancing its diagnostic technologies. This initiative is expected to enhance the company's market position and potentially improve its financial performance, which has been a focal point for investors.

Market sentiment towards Bluejay Diagnostics has been varied, with some analysts issuing buy signals based on short-term moving averages. However, the overall market activity and the company's financial health remain under close scrutiny by investors and analysts.